Abstract
Multiplex biomarker tests are becoming an essential part of the drug development process. This chapter explores the role of biomarker-based tests as effective tools in improving preclinical research and clinical development, and the challenges that this presents. The potential of incorporating biomarkers in the clinical pipeline to improve decision making, accelerate drug development, improve translation, and reduce development costs is discussed. This chapter also discusses the latest biomarker technologies in use to make this possible and details the next steps that must undertaken to keep driving this process forwards.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Hughes JP, Rees S, Kalindjian SB, Philpott KL (2011) Principles of early drug discovery. Br J Pharmacol 162:1239–1249
Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300:1887–1896
McNaughton R, Huet G, Shakir S (2013) An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open 4:e004221
Onakpoya IJ, Heneghan CJ, Aronson JK (2016) Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med 14:10
Rawson NS (2016) Drug safety: withdrawn medications are only part of the picture. BMC Med 14:28
Ovens J (2006) Funding for accelerating drug development initiative critical. Nat Rev Drug Discov 5:271
http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
Need AC, Motulsky AG, Goldstein DB (2005) Priorities and standards in pharmacogenetic research. Nat Genet 37:671–681
http://www.fda.gov/ohrms/dockets/ac/98/briefingbook/1998-3454B1_03_WL50.pdf
Cohen JS (2006) Risks of troglitazone apparent before approval in USA. Diabetologia 49:1454–5145
Onakpoya IJ, Heneghan CJ, Aronson JK (2016) Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol 3:1–13 [Epub ahead of print]
Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B et al (2011) Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics 21:280–288
Choi S (2003) Nefazodone (Serzone) withdrawn because of hepatotoxicity. CMAJ 169:1187
Dogné JM, Hanson J, Supuran C, Pratico D (2006) Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 12:971–975
Sheridan C (2006) TeGenero fiasco prompts regulatory rethink. Nat Biotechnol 24:475–476
Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Biomarkers Definitions Working Group et al (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95
Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr (1997) Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 43:1749–1756
Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867
Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR et al (1999) Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17:676–682
Griffin JL (2003) Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol 7:648–654
Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC et al (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2:2692–2703
Imming P, Sinning C, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5:821–834
Sioud M (2007) Main approaches to target discovery and validation. Methods Mol Biol 360:1–12
Spaethling JM, Sanchez-Alavez M, Lee J, Xia FC, Dueck H, Wang W (2016) Single-cell transcriptomics and functional target validation of brown adipocytes show their complex roles in metabolic homeostasis. FASEB J 30:81–92
Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A et al (2013) Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. Mol Cancer 12:11
Prosser GA, de Carvalho LP (2013) Metabolomics reveal d-alanine:d-alanine ligase as the target of d-cycloserine in Mycobacterium tuberculosis. ACS Med Chem Lett 4:1233–1237
Amacher DE (2010) The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol Appl Pharmacol 245:134–142
Meneses-Lorente G, Watt A, Salim K, Gaskell SJ, Muniappa N, Lawrence J et al (2006) Identification of early proteomic markers for hepatic steatosis. Chem Res Toxicol 19:986–998
Tang H, Panemangalore R, Yarde M, Zhang L, Cvijic ME (2016) 384-well multiplexed luminex cytokine assays for lead optimization. J Biomol Screen. pii: 1087057116644164. (Epub ahead of print)
Valet G (2006) Cytomics as a new potential for drug discovery. Drug Discov Today 11:785–791
Gale EA (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875
Suter L, Schroeder S, Meyer K, Gautier JC, Amberg A, Wendt M et al (2010) EU framework 6 project: predictive toxicology (PredTox)--overview and outcome. Toxicol Appl Pharmacol 252:73–84
Afshari CA, Hamadeh HK, Bushel PR (2011) The evolution of bioinformatics in toxicology: advancing toxicogenomics. Toxicol Sci 120(S1):S225–S237
Bulera SJ, Eddy SM, Ferguson E, Jatkoe TA, Reindel JF, Bleavins MR et al (2001) RNA expression in the early characterization of hepatotoxicants in Wistar rats by high-density DNA microarrays. Hepatology 33:1239–1258
Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich RG (2001) Microarray analysis of hepatotoxins in vitro reveals a correlation between geneexpression profiles and mechanisms of toxicity. Toxicol Lett 120:359–368
Verret V, Namur J, Ghegediban SH, Wassef M, Moine L, Bonneau M et al (2013) Toxicity of doxorubicin on pig liver after chemoembolization with doxorubicin-loaded microspheres: a pilot DNA-microarrays and histology study. Cardiovasc Intervent Radiol 36:204–312
Tsuchiya H, Sato J, Tsuda H, Fujiwara Y, Yamada T, Fujimura A et al (2013) Serum amyloid A upsurge precedes standard biomarkers of hepatotoxicity in ritodrine-injected mice. Toxicology 305:79–88
Andersson U, Lindberg J, Wang S, Balasubramanian R, Marcusson-Ståhl M, Hannula M et al (2009) A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers 14:572–586
Meneses-Lorente G, Guest PC, Lawrence J, Muniappa N, Knowles MR, Skynner HA et al (2004) A proteomic investigation of drug-induced steatosis in rat liver. Chem Res Toxicol 17:605–612
Killestein J, Polman CH (2011) Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 7:221–228
Gerger A, Labonte M, Lenz HJ (2011) Molecular predictors of response to antiangiogenesis therapies. Cancer J 17:134–141
Flood DG, Marek GJ, Williams M (2011) Developing predictive CSF biomarkers-A challenge critical to success in Alzheimer’s disease and neuropsychiatric translational medicine. Biochem Pharmacol 81:1422–1434
Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY et al (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453–459
Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M et al (2010) Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 91:950–907
Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X et al (2013) Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 108:1052–1060
Poste G (2011) Bring on the biomarkers. Nature 469:156–157
Schumacher S, Nestler J, Otto T, Wegener M, Ehrentreich-Förster E, Michel D et al (2012) Highly-integrated lab-on-chip system for point-of-care multiparameter analysis. Lab Chip 12:464–473
Berg B, Cortazar B, Tseng D, Ozkan H, Feng S, Wei Q et al (2015) Cellphone-based hand-held micro-plate reader for point-of-care testing of enzyme-linked immunosorbent assays. ACS Nano 9:7857–7866
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Rahmoune, H., Guest, P.C. (2017). Application of Multiplex Biomarker Approaches to Accelerate Drug Discovery and Development. In: Guest, P.C. (eds) Multiplex Biomarker Techniques. Methods in Molecular Biology, vol 1546. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-6730-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6730-8_1
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-6729-2
Online ISBN: 978-1-4939-6730-8
eBook Packages: Springer Protocols